VARIABILITY OF ADIPONECTIN LEVELS AT DIFFERENT STAGES OF ATHEROGENESIS, FROM OBESITY TO ADVANCED ATHEROSCLEROSIS AND HEART FAILURE  by Antonopoulos, Alexis S. et al.
A35.E338
JACC March 9, 2010
Volume 55, issue 10A
 CARDIAC FUNCTION AND HEART FAILURE 
VARIABILITY OF ADIPONECTIN LEVELS AT DIFFERENT STAGES OF ATHEROGENESIS, FROM OBESITY TO 
ADVANCED ATHEROSCLEROSIS AND HEART FAILURE
ACC Poster Contributions
Georgia World Congress Center, Hall B5
Tuesday, March 16, 2010, 9:30 a.m.-10:30 a.m.
Session Title: Myocardial Fibrosis and Cardiac MRI
Abstract Category: Myocardial Function/Heart Failure--Clinical Nonpharmacological Treatment
Presentation Number: 1230-39
Authors: Alexis S. Antonopoulos, Charalambos Antoniades, Dimitris Tousoulis, Antigoni Miliou, Constantinos Bakogiannis, Kyriakoula Marinou, Michael 
Dimosthenous, Costas Psarros, Keith M. Channon, Christodoulos Stefanadis, 1st Cardiology Department Hippokration Hospital, Athens, Greece, 
University of Oxford, Oxford, United Kingdom
Background: Adiponectin is down-regulated in obesity, but its role at different stages of ischaemic heart disease is controversial. We evaluated the 
impact of obesity and the different stages of ischaemic heart disease on circulating adiponectin levels.
Methods: Serum adiponectin was measured in 746 individuals: 283 healthy non-obese individuals (BMI<28Kg/m2), 283 patients with coronary 
artery disease (CAD) and normal left ventricular ejection fraction (EF), 225 patients with ischaemic heart failure (IHD, EF<40%) and 34 patients with 
non-ischemic heart failure (HF, EF<40% and no CAD).
Results: Obesity was associated with lower adiponectin levels among healthy individuals (Fig.). However, serum adiponectin was higher in CAD vs 
obese or non-obese healthy individuals, while heart failure induced a striking elevation of serum adiponectin, independently of the underlying CAD 
(Fig.). Adiponectin was correlated negatively with EF (r=-0.414, p=0.0001) but positively with the angiographic extend of CAD (rho=0.111, p=0.008).
Conclusions: Despite the down-regulation of adiponectin’s expression in obese individuals, its serum levels are elevated in patients with CAD, 
while the development of ischaemic- or non-ischaemic heart failure induces a striking up-regulation of adiponectin’s synthesis. This is the first 
comprehensive study demonstrating that further to obesity, the extent of coronary atherosclerosis and the development of heart failure are key 
determinants of circulating adiponectin.
